The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
Pulmonary arterial hypertension: pathogenesis and clinical management
Open accessAbstract
Pulmonary hypertension is defined as a resting mean pulmonary artery pressure of 25 mm Hg or above. This review deals with pulmonary arterial hypertension (PAH), a type of pulmonary hypertension that primarily affects the pulmonary vasculature. In PAH, the pulmonary vasculature is dynamically obstructed by vasoconstriction, structurally obstructed by adverse vascular remodeling, and pathologically non-compliant as a result of vascular fibrosis and stiffening. Many cell types are abnormal in PAH, including vascular cells (endothelial cells, smooth muscle cells, and fibroblasts) and inflammatory cells. Progress has been made in identifying the causes of PAH and approving new drug therapies. A cancer-like increase in cell proliferation and resistance to apoptosis reflects acquired abnormalities of mitochondrial metabolism and dynamics. Mutations in the type II bone morphogenetic protein receptor (BMPR2) gene dramatically increase the risk of developing heritable PAH. Epigenetic dysregulation of DNA methylation, histone acetylation, and microRNAs also contributes to disease pathogenesis. Aberrant bone morphogenetic protein signaling and epigenetic dysregulation in PAH promote cell proliferation in part through induction of a Warburg mitochondrial-metabolic state of uncoupled glycolysis. Complex changes in cytokines (interleukins and tumor necrosis factor), cellular immunity (T lymphocytes, natural killer cells, macrophages), and autoantibodies suggest that PAH is, in part, an autoimmune, inflammatory disease. Obstructive pulmonary vascular remodeling in PAH increases right ventricular afterload causing right ventricular hypertrophy. In some patients, maladaptive changes in the right ventricle, including ischemia and fibrosis, reduce right ventricular function and cause right ventricular failure. Patients with PAH have dyspnea, reduced exercise capacity, exertional syncope, and premature death from right ventricular failure. PAH targeted therapies (prostaglandins, phosphodiesterase-5 inhibitors, endothelin receptor antagonists, and soluble guanylate cyclase stimulators), used alone or in combination, improve functional capacity and hemodynamics and reduce hospital admissions. However, these vasodilators do not target key features of PAH pathogenesis and have not been shown to reduce mortality, which remains about 50% at five years. This review summarizes the epidemiology, pathogenesis, diagnosis, and treatment of PAH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–217 of 217
Prins, K. W., Duval, S., Markowitz, J., PRITZKER, M. R., & Thenappan, T. (2016) · Pulmonary Circulation · doi:10.1086/690017 · Cited by 80
Self-citationLeukotriene B 4 Activates Pulmonary Artery Adventitial Fibroblasts in Pulmonary Hypertension
Qian, J., Tian, W., Jiang, X., Tamošiūnienė, R., Sung, Y. K., Shuffle, E. M., Tu, A. B., Valenzuela, A., Jiang, S. Y., Zamanian, R. T., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.06370 · Cited by 79
Right Isovolumic Contraction Velocity Predicts Survival in Pulmonary Hypertension
Ernande, L., Cottin, V., Leroux, P.-Y., Girerd, N., Huez, S., Mulliez, A., Bergerot, C., Ovize, M., Mornex, J., Cordier, J.-F., et al. (2012) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2012.11.011 · Cited by 74
Arterial Stiffness: A Novel Risk Factor for Kidney Injury Progression?
Georgianos, P. I., Sarafidis, P. A., & Liakopoulos, V. (2015) · American Journal of Hypertension · doi:10.1093/ajh/hpv004 · Cited by 73
Machuca, T., & de Perrot, M. E. (2015) · Circulation · doi:10.1161/circulationaha.114.012593 · Cited by 62
Decoene, C., Bourzoufi, K., Moreau, D., Narducci, F., Crepin, F., & Krivosic-Horber, R. (2001) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/bf03016836 · Cited by 58
Pulmonary Arterial Hypertension and the Sex Hormone Paradox
Foderaro, A. E., & Ventetuolo, C. E. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0689-7 · Cited by 58
miR-26a Linked to Pulmonary Hypertension by Global Assessment of Circulating Extracellular MicroRNAs
Schlosser, K., White, R. J., & Stewart, D. J. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1403le · Cited by 54
Athymic Nude Rats Develop Severe Pulmonary Hypertension following Monocrotaline Administration
Miyata, M., Sakuma, F., Ito, M., Ohira, H., Sato, Y., & Kasukawa, R. (2000) · International Archives of Allergy and Immunology · doi:10.1159/000024324 · Cited by 51
McLaughlin, V. V., Channick, R. W., Chin, K., Frey, A., Gaine, S., Ghofrani, H. A., Hoeper, M. M., Lang, I. M., Preiss, R., Rubin, L. J., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(15)61538-8 · Cited by 47
Addetia, K., Bhave, N. M., Tabit, C. E., Gomberg‐Maitland, M., Freed, B. H., Dill, K. E., Lang, R. M., Mor‐Avi, V., & Patel, A. R. (2013) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.113.000932 · Cited by 44
Bhave, N. M., Patel, A. R., Weinert, L., Yamat, M., Freed, B. H., Mor‐Avi, V., Gomberg‐Maitland, M., & Lang, R. M. (2013) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2013.05.007 · Cited by 40
Pulmonary Artery Wedge Pressure Relative to Exercise Work Rate in Older Men and Women
Esfandiari, S., Wright, S. P., Goodman, J. M., Sasson, Z., & Mak, S. S. (2017) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001227 · Cited by 38
Chua, S. O., Levine, R. A., Yosefy, C., Handschumacher, M. D., Chu, J. W., Qureshi, A. M., Neary, J., Ton-Nu, T.-T., Fu, M., Wu, C., et al. (2009) · European Journal of Echocardiography · doi:10.1093/ejechocard/jep013 · Cited by 36
One-year experience with intravenous treprostinil for pulmonary arterial hypertension
Benza, R. L., Tapson, V. F., Gomberg‐Maitland, M., Poms, A., Barst, R. J., & McLaughlin, V. V. (2013) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2013.06.008 · Cited by 35
Cavasin, M. A., Stenmark, K. R., & McKinsey, T. A. (2015) · Pulmonary Circulation · doi:10.1086/679700 · Cited by 33
Momparler, R. L., Côté, S., Momparler, L. F., & Idaghdour, Y. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00019 · Cited by 28
Cited by
Mitochondria in health, disease, and aging
Harrington, J. S., Ryter, S. W., Plataki, M., Price, D. R., & Choi, A. M. K. (2023) · Physiological Reviews · doi:10.1152/physrev.00058.2021 · Cited by 602
Hallmarks of Endothelial Cell Metabolism in Health and Disease
Li, X., Sun, X., & Carmeliet, P. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.011 · Cited by 453
Mocumbi, A., Humbert, M., Saxena, A., Jing, Z.-C., Sliwa, K., Thienemann, F., Archer, S. L., & Stewart, S. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00486-7 · Cited by 370
Self-citationEndothelin: 30 Years From Discovery to Therapy
Barton, M., & Yanagisawa, M. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12105 · Cited by 295
Targeting SOCS proteins to control JAK-STAT signalling in disease
Durham, G. A., Williams, J. J. L., Nasim, M. T., & Palmer, T. M. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.03.001 · Cited by 183
Metadata
- Authors
- Thenappan, T., Ormiston, M. L., Ryan, J. J., & Archer, S. L.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2018-03-14
- Volume
- 360
- Pages
- j5492
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- OpenAlex
- W2789769541
- Cited by
- 998
- References
- 217
- FWCI
- 50.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.